الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 16 |  |  |
| | | from | 16 | | |
Abstract
Summary
Acute myocardial infarction remains a leading cause of
morbidity and mortality worldwide. It occurs when
irreversible myocardial cell damage or death occurs.
STEMI is caused by occlusion of major coronary artery and
primary percutaneous coronary intervention is the preferred
reperfusion strategy especially when performed by an
experienced team within the shortest possible time from first
medical contact.
Activated platelets participate to produce inflammatory
substances from endothelial cells and leucocytes that cause
monocyte adhesion and thereby increase the inflammatory
process and progression of atherosclerotic plaque.
Lymphocyte play a dominant role in chronic inflammation
of atherosclerosis, and lower lymphocyte count is associated
with increased cardiovascular risk and mortality in acute
myocardial infarction (AMI).
In this study, we assessed the PLR as an indicator of nonereflow
after PPCI in patient presented with STEMI. 100
patients were selected, in our institution, presented with
STEMI, CBC (complete blood count) was done and platelet
to lymphocyte ratio was calculated.
PLR on admission was significantly higher in postintervention
none-reflow group. There was a large number
of diabetic patient in the none - reflow group.
In conclusion, different from other inflammatory markers
and assays, PLR is inexpensive and readily available
biomarkers that may be useful as predictor of none reflow
following PPCI in patients with STEMI.